30 closest matches · ranked by relevance
Acute Myelogenous Leukemia · Acute Lymphocytic Leukemia · Chronic Myelogenous Leukemia
Primary: Percentage of Participants With Overall Survival — 73; 65 percentage of participants — p=0.17
Hematological Malignancies
Primary: Percentage of Participants Alive at 1 Year After Transplant — 40 percentage of participants
Chronic Myelogenous Leukemia (CML) · Acute Myelogenous Leukemia (AML) · Myelodysplastic Syndrome
Primary: Number of Participants With Engraftment — 29 Participants
Leukemia · Myelodysplasia · Acute Lymphocytic Leukemia
Primary: Number of Successful Unrelated Cord Blood (UCB) Transplants — 2 participants
Hematologic Malignancies · Disorder Related to Transplantation · Hematopoietic Malignancy
Primary: Event Free Survival (EFS) for Research Participants — 4 Participants
Acute Myeloid Leukemia · Acute Lymphocytic Leukemia · Chronic Myelogenous Leukemia
Primary: Number of Participants Who Were Alive at 1 Year Transplant Overall Survival — 130 Participants
Leukemia · Myelodysplastic Syndrome · Non-Hodgkins Lymphoma
Primary: Progression Free Survival/PFS at 1 Year Post UCBT. — 84 percentage of participants
Congenital Pediatric Disorders
Primary: Overall Survival at 100 Days After Umbilical Cord Blood Transplant in Pediatric Patients. — 0.947 probability of overall survival
Cancer · Leukemia · Myelodysplastic Syndrome
Primary: Overall Response — 24; 3 participants
Multiple Myeloma · Leukemia · Lymphoma
Primary: Number of Participants With Engraftment — 27 participants
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome · Adult Acute Lymphoblastic Leukemia in Remission · Adult Acute Megakaryoblastic Leukemia (M7)
Primary: Overall Survival — 8 Participants
Leukemia · Myelodysplastic Syndromes · Childhood Acute Myeloid Leukemia in Remission
Primary: Incidence of Engraftment — 100; 93; 100 Percentage of participants
Non-Hodgkin's Lymphoma · Hodgkin's Lymphoma · Multiple Myeloma
Primary: Number of Participants With a Clinically Significant Infection — 12; 14; 5 Participants
Graft Versus Host Disease · Leukemia · Lymphoma
Primary: Overall Response Rate — 12; 1; 7 Participants
Acute Leukemia · Acute Myeloid Leukemia · Acute Lymphoblastic Leukemia/Lymphoma
Primary: Probability of Acute Graft Versus Host Disease (GVHD) — 0; 30 Percent of participants
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Leukemia, Myeloid, Acute · Burkitt Lymphoma
Primary: Overall Survival at 180 Days From the Time of Transplant — 73.5; 54.0 percentage of participants
Hematologic Malignancy · Myelodysplastic Syndrome (MDS) · Aplastic Anemia
Primary: The Number of Participants Reaching Primary Endpoint of Absolute Neutrophil Count (ANC) of 500/uL (Engraftment). — 3 participants
Myeloid Hematological Malignancies
Primary: Overall Survival at 100 Days, 1 Year, and 3 Years After Umbilical Cord Blood Transplant in Pediatric Patients. — 0.923; 0.923; 0.923 probability of overall survival
Acute Lymphoblastic Leukemia · Acute Myeloid Leukemia · Aggressive Non-Hodgkin Lymphoma
Primary: Overall Survival — 35 percent of patients
Myeloproliferative Disorders · Leukemia · Lymphoma
Primary: Number of Participants Who Were Alive at 1 Year Post Transplant — 59; 40; 1; 26 Participants
Acute Lymphocytic Leukemia · Acute Myelogenous Leukemia · Burkitt's Lymphoma
Primary: Percentage of Participants With Progression Free Survival (PFS) — 35.0; 41.1 percentage of participants — p=0.4092
Leukemia · Myelodysplastic Syndrome · Lymphoma
Primary: Percent of Engrafted Participants With Successful Neutrophil Recovery — 96 % w/incidence of neutrophil recovery
Acute Biphenotypic Leukemia · Acute Lymphoblastic Leukemia · Acute Myeloid Leukemia
Primary: Overall Survival — 28; 15; 53; 7 Participants
Leukemia, Lymphocytic, Acute · Leukemia, Myelocytic, Acute · Leukemia, Myeloid, Chronic
Primary: Time To Neutrophil Engraftment — 17; 15 Days
Hematologic Disorders
Primary: The Number of Patients With Successful Engraftment — 144 Participants
Non Malignant Disorders · Immunodeficiencies · Congenital Marrow Failures
Primary: Determine the Feasibility of Attaining Acceptable Rates of Donor Cell Engraftment (>25% Donor Cells at 180 Days) Following RIC Regimens in Children < 21 Years Receiving…
Sickle Cell Disease & Thalassemia
Primary: Safety and Tolerability Will be Measured by Acute NiCord® Infusional Toxicity. — 0; 0; 3; 0 participants
Autism Spectrum Disorder · Autism
Primary: A Number of Participants With Non-serious and Serious Adverse Events 24 Hrs Post-transfusion — 0; 0; 0; 0 participants
Acute Myeloid Leukemia · Acute Lymphoblastic Leukemia · Myelodysplastic Syndrome (MDS)
Primary: Safety of HBO Administration in the Setting of UCB Stem Cell Transplantation — 15; 12; 12; 13 Participants
Hematological Malignancies · Acute Lymphoblastic Leukemia (ALL) · Acute Myeloid Leukemia (AML)
Primary: Engraftment — 94 percentage of patients